MLXIPL and metabolic dysfunction-associated steatotic liver disease: AMPK (AMP-activated protein kinase), a critical regulator of metabolic processes in diseases like NAFLD, suppresses DNL by inhibiting both SREBP1c and ChREBP, thus reducing lipogenesis and helping to counteract lipid accumulation in the liver [3].